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ABSTRACT
Objectives This study aims to determine the proportion 
of real-world patients with myocardial infarction (MI) 
who would have been eligible for the PEGASUS-TIMI 54 
(Prevention of Cardiovascular Events in Patients with 
Prior Heart Attack Using Ticagrelor Compared to Placebo 
on a Background of Aspirin-Thrombolysis in Myocardial 
Infarction 54) trial, to characterise their current use of 
P2Y12 inhibitors and to explore the estimated costs and 
ischaemic event consequences of increasing P2Y12 
inhibitor use among these patients.
Methods In the US national ACTION Registry–GWTG 
(Acute Coronary Treatment and Intervention Outcomes 
Network Registry–Get With The Guidelines), we identified 
273 328 patients with MI and determined the proportion 
that would have met the eligibility criteria for the PEGASUS 
trial. We described longitudinal P2Y12 inhibitor use among 
patients eligible for PEGASUS and estimated the cost and 
ischaemic consequences of increasing P2Y12 use among 
eligible patients.
Results A total of 112 222 (41.1%) patients with MI in 
ACTION Registry–GWTG met eligibility for the PEGASUS 
trial. Among 83 871 eligible patients with pharmacy claims 
data, 23 042 (27.5%) were on a P2Y12 inhibitor at 1 year, 
9661 (11.5%) at 2 years and 5246 (6.3%) at 3 years, with 
the majority (79.2%) of these patients on clopidogrel. 
The use of ticagrelor in eligible patients not yet on a 
P2Y12 inhibitor at 1 year post-MI would cost an estimated 
US$885 000 per MI, stroke or cardiovascular death averted 
over a 3-year time horizon, while the use of clopidogrel 
would cost an estimated US$19 800 per ischaemic event 
averted.
Conclusion In contemporary clinical practice, a minority 
of patients are on a P2Y12 inhibitor beyond 1-year post-MI. 
Applying PEGASUS trial findings to clinical practice would 
result in a large increase in P2Y12 inhibitor use, with a cost 
per ischaemic event averted that is strongly influenced by 
the choice of therapy.
INTRODUCTION
The activated platelet is a key contributor to the 
pathobiology of acute coronary events.1 Dual 
antiplatelet therapy (DAPT) with aspirin, and 
a P2Y12 inhibitor has been shown to reduce 
the risk of ischaemic events in patients with an 
acute coronary syndrome (ACS).2 The benefit 
of long-term P2Y12 therapy for patients with 
stable cardiovascular disease is less clear. A 
randomised trial of long-term clopidogrel on 
background aspirin therapy did not demon-
strate benefit in a broad population at risk 
of atherosclerotic events.3 However, post hoc 
analyses suggested the addition of clopido-
grel to aspirin resulted in benefit for certain 
patient subgroups, including those with a 
prior history of myocardial infarction (MI).4 
These findings implicated potential benefit 
of long-term DAPT in specific subgroups of 
patients at high risk of ischaemic events.5–7
Newer generation P2Y12 receptor antag-
onists are characterised by greater platelet 
inhibition, less variability in clinical 
response, and superior efficacy compared 
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Coronary artery disease
KEY QUESTIONS
What is already known about this subject?
The PEGASUS-TIMI 54 (Prevention of Cardiovascular 
Events in Patients with Prior Heart Attack Using 
Ticagrelor Compared to Placebo on a Background 
of Aspirin-Thrombolysis in Myocardial Infarction 54) 
trial demonstrated a reduction in ischaemic events 
following P2Y12 inhibition with ticagrelor among 
patients with a prior myocardial infarction (MI). The 
implications of these findings for clinical practice are 
unknown.
What does this study add?
Less than half of all stable patients with post-MI in 
routine US clinical practice met the PEGASUS eligibility 
criteria. Furthermore, P2Y12 inhibitors were infrequently 
used in the long-term management of patients with 
MI in the ACTION Registry–GWTG (Acute Coronary 
Treatment and Intervention Outcomes Network 
Registry–Get With The Guidelines). The estimated cost 
per ischaemic event averted with increasing P2Y12 
inhibitor use is nearly 45-fold larger with long-term 
ticagrelor than with generic clopidogrel.
How might this impact on clinical practice?
Applying PEGASUS trial findings to clinical practice 
would result in a large increase in P2Y12 inhibitor 
use. Given the cost implications for different P2Y12 
inhibitors, additional study of long-term P2Y12 inhibitors 
on patient outcomes and cost of care is needed to 
guide optimal use of this therapy in clinical practice.
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with clopidogrel following an ACS.8 9 The recent 
PEGASUS-TIMI 54 (Prevention of Cardiovascular 
Events in Patients with Prior Heart Attack Using Tica-
grelor Compared to Placebo on a Background of 
Aspirin-Thrombolysis in Myocardial Infarction 54) 
trial sought to determine whether the benefit of tica-
grelor, a newer generation P2Y12 inhibitor, extends to 
stable patients with a remote history of MI.10 The study 
found that ticagrelor use, with background aspirin 
therapy, resulted in a 1.2% absolute reduction in the 
rate of cardiovascular death, MI or stroke over 3 years 
compared with aspirin alone.11
Although the PEGASUS trial findings suggest an 
intriguing opportunity to improve outcomes of patients 
with prior MI, patients seen in routine clinical practice 
may differ from those enrolled in clinical trials.12 Conse-
quently, the prevalence of stable patients with MI in 
US clinical practice who would meet PEGASUS enrol-
ment criteria for long-term therapy with P2Y12 therapy is 
unknown. In addition, given the prior post hoc analysis 
of long-term therapy with clopidogrel4 and recent data 
demonstrating benefit to prolonged P2Y12 following PCI,
13 
many patients with a remote history of MI may already be 
on some form of long-term P2Y12 inhibitor. Finally, clopi-
dogrel became available as a generic prescription in May, 
2012, while ticagrelor remains on patent until 2018. As a 
result, there may be cost differences in consideration of 
long-term P2Y12 inhibitor use.
Answers to these questions can be measured using 
clinical registries, such as the American College of Cardi-
ology (ACC) National Cardiovascular Disease Registry 
(NCDR) programs. The ACC has recently launched the 
Research to Practice initiative (formerly titled Rapid 
Registry Response), which facilitates rapid analysis of 
registry data to understand how clinical trials, such as 
PEGASUS, inform clinical practice.14 Accordingly, we 
used this initiative and the NCDR ACTION Registry 
to determine the proportion of real-world patients 
with post-MI who would be eligible for the PEGASUS 
trial, characterise their use of P2Y12 inhibitors and 
model the costs and ischaemic clinical consequences of 
adding long-term P2Y12 therapy in accordance with the 
PEGASUS trial.
METHODS
Data source
The NCDR ACTION Registry–GWTG (Acute Coro-
nary Treatment and Intervention Outcomes Network 
Registry–Get With The Guidelines) is a US national 
quality improvement registry of ST-segment elevation 
MI (STEMI) and non-STEMI (NSTEMI) patients.15 
Trained staff extracts data from medical records into a 
Web-based case record without direct patient contact. 
A listing of specific data fields and their definitions is 
available (http://www. ncdr. com/ WebNCDR/ ACTION/ 
Elements. aspx). Our study cohort was derived from 
patients presenting with their first MI in the registry from 
1 October 2010 to 30 April 2013 at ACTION Registry–
GWTG participating hospitals.
To identify long-term use of DAPT, data from ACTION 
Registry–GWTG were linked with pharmacy claims data 
from Symphony Health Solutions, a multichannel claims 
data resource that includes all payer types, including cash 
self-pay, and covers pharmacy activity in all 50 US states. 
The data warehouse captures dispensed prescription 
drugs from claims clearing-houses, retail pharmacies and 
prescription benefit managers for approximately 70% 
of US retail pharmacy transactions. Records comprise 
National Council for Prescription Drug Program 
formatted claims, which include the date of a given phar-
macy fill, national drug code, drug name and dosage, as 
well as other standardised fields.16
Patient population
We replicated the inclusion and exclusion criteria from 
the PEGASUS-TIMI 54 trial to identify patients for whom 
the findings of this trial may apply.10 11 Accordingly, we 
identified all patients with an index MI during the study 
period and then restricted our cohort to patients in the 
ACTION Registry–GWTG who were 65 years or older 
at the time of their index MI or who were aged 50 or 
older at the time of the index MI with one or more addi-
tional risk factors of prior MI, diabetes mellitus on oral 
medications or insulin, or known multivessel coronary 
disease. Although PEGASUS also included patients aged 
50 or older with an additional risk factor of non-end-stage 
chronic renal dysfunction, ACTION Registry–GWTG 
data are insufficiently granular to identify patients with 
this additional risk factor.
In accordance with PEGASUS enrolment criteria, 
we excluded patients receiving chronic anticoagula-
tion at discharge from the index MI and patients with 
prior stroke, coronary artery bypass grafting (CABG) in 
the past 5 years or renal failure requiring dialysis. The 
ACTION Registry–GWTG lacks data for several comorbid 
conditions that were exclusion criteria for PEGASUS. As 
a result, we could not identify patients with a history of 
gastrointestinal bleed in the past 6 months, surgery in the 
past 30 days, central nervous system tumour, intracranial 
vascular abnormality, prior intracranial haemorrhage or 
severe liver disease that would have been excluded from 
the PEGASUS trial.
The final analytic cohort included patients eligible for 
the PEGASUS trial with at least 3 years of prescription 
claims after the cohort eligibility date.
Use of P2Y12 inhibitors 1 year post-MI
Patients were categorised as users of a P2Y12 inhibitor at 
1 year post-MI if they had a pharmacy claim for a P2Y12 
inhibitor in the first 3 months that followed 1 year from 
the index MI. This approach was repeated in years 2 and 
3 to establish continued use of P2Y12 inhibitors. Because 
aspirin is available over the counter, the concurrent use 
of aspirin could not be reliably confirmed.
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Statistical analysis
We identified patients from the ACTION Registry–
GWTG who met PEGASUS inclusion and exclusion 
criteria and compared the cohort with patients from the 
PEGASUS trial. Among patients eligible for PEGASUS 
in the ACTION Registry–GWTG, we then compared 
patient demographics (age, sex, race/ethnicity and 
insurance status), comorbidities (hypertension, hyper-
lipidaemia, diabetes, tobacco use, prior MI, prior 
percutaneous coronary intervention (PCI), prior 
CABG, prior heart failure, cerebrovascular disease, 
chronic kidney disease, chronic lung disease and 
anaemia), clinical presentation (STEMI or NSTEMI), 
management (PCI, CABG or medical management 
alone) and estimated bleeding risk, by the use of P2Y12 
inhibitors at 1 year after the index MI. Bleeding risk 
was estimated through the application of a previously 
validated model from the ACTION Registry–GWTG.17 
We then assessed the current use of P2Y12 inhibitors at 
1, 2 and 3 years post-MI in our cohort and the specific 
P2Y12 inhibitors used. Cohort differences were assessed 
using analysis of variance for continuous variables and 
χ² test for categorical variables.
In the cost and ischaemic clinical consequences analysis, 
we first determined the cost of increasing the use of P2Y12 
inhibitors in the eligible cohort. We estimated the cost of 
placing all patients eligible for PEGASUS who were not 
on a P2Y12 inhibitor at year 1 post-MI on ticagrelor for a 
3-year time horizon, as reported in the clinical trial. The 
cost of ticagrelor was estimated based on the Wholesale 
Acquisition Cost. Generally, Wholesale Acquisition Cost is 
the price established by the drug manufacturer before any 
rebates, discounts, allowances or other price concessions 
are offered by the supplier of the product. We also esti-
mated the cost of clopidogrel therapy in all patients eligible 
for PEGASUS who were not on a P2Y12 inhibitor at year 1 
post-MI using the same methods.
To estimate the ischaemic clinical consequences of 
placing all patients eligible for PEGASUS who were not 
on a P2Y12 inhibitor at year 1 post-MI on ticagrelor, we 
applied the point estimate for the clinical effect reported 
in the PEGASUS trial over a 3-year time horizon.11 We 
estimated the number of prevented cardiovascular 
events due to ticagrelor therapy by multiplying eligible 
patients by the average effect size for cardiovascular 
events reported in the PEGASUS trial (1.27% 3-year abso-
lute risk reduction). Because a randomised comparison 
of the clinical effect of clopidogrel versus ticagrelor in 
stable patients with post-MI has yet to be completed and 
the point estimate for the clinical effect of clopidogrel in 
a post hoc analysis of the CHARISMA (Clopidogrel for 
High Atherothrombotic Risk and Ischemic Stabilization, 
Management, and Avoidance) trial (30-month absolute 
risk reduction of 1.7%) is larger than that reported for 
ticagrelor in PEGASUS, we estimated the clinical conse-
quences of adding clopidogrel therapy by applying the 
same point estimate used in our base case evaluation of 
ticagrelor.4 Clopidogrel was chosen for this analysis given 
prior studies of this therapy in similar clinical settings to 
the PEGASUS trial and because clopidogrel is available 
as a generic medication. In sensitivity analyses, we varied 
the estimated clinical efficacy of these P2Y12 therapies 
by 25% above and below the point estimate from the 
randomised trials to provide a range of the potential cost 
consequences of expanding therapy. We applied similar 
methods in the estimation of additional bleeding events 
related to increased ticagrelor use (1.24% 3-year abso-
lute bleeding risk increase with ticagrelor 60 mg in the 
PEGASUS trial).
RESULTS
We identified 273 328 patients with an index MI in the 
ACTION Registry–GWTG during the period of study. 
After applying inclusion and exclusion criteria from the 
PEGASUS trial, 112 222 (41.1%) of these patients met 
enrolment criteria for the trial (figure 1). We were able 
to match 83 871 (74.7%) of these patients to Symphony 
pharmaceutical claims data to assess P2Y12 inhibitor 
use between 1 and 3 years post-MI. Characteristics for 
patients for the PEGASUS trial randomised to 60 mg tica-
grelor are descriptively compared with patients eligible 
for PEGASUS in the ACTION Registry–GWTG in table 1 
without statistical tests of significance, given the lack of 
patient-level data from the PEGASUS trial for the present 
study. Patients eligible for PEGASUS in the ACTION 
Registry–GWTG appeared to be older, were more often 
female, less often presented with a STEMI and were more 
likely to suffer an MI or stroke in the 3-year follow-up.
At 1-year post-MI, 23 042 (27.5%) of patients eligible 
for PEGASUS in the ACTION Registry–GWTG were on a 
P2Y12 inhibitor. The majority of patients on a P2Y12 inhib-
itor were on clopidogrel (79.2%), followed by prasugrel 
(17.7%) and ticagrelor (3.0%). Patient characteristics 
by use of P2Y12 inhibitors at 1 year post-MI are shown in 
table 2. Given the size of our cohort, many differences were 
statistically significant, although the absolute differences 
were generally small, with some exceptions. Compared 
with patients who were not on a P2Y12 inhibitor at 1 year 
post-MI, patients on a P2Y12 inhibitor were more likely 
to have private insurance (30.7% vs 23.2%, p <0.001) or 
received PCI with a drug-eluting stent (65.5% vs 36.9%) 
and less likely to have prior MI (16.5% vs 19.7%, p <0.001) 
or anaemia (17.9% vs 24.6%). Compared with patients 
who were not on a P2Y12 inhibitor at 1 year, estimated 
bleeding risk was slightly lower among patients on P2Y12 
therapy (moderate risk 27.5% vs 30.1%, high risk 2.4% vs 
4.0%; p <0.001).
The number of patients on a P2Y12 inhibitor declined 
over time to 9661 (11.5%) at 2 years post-MI and 5246 
(6.3%) at 3 years post-MI (figure 2). Characteristics of 
patients on a P2Y12 inhibitor at 1, 2 and 3 years post-MI 
were largely similar (table 3).
The Wholesale Acquisition Cost for a 1-year supply 
of 60 mg ticagrelor two times per day was US$3750. 
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The estimated cost of initiating and continuing tica-
grelor for a 3-year time horizon in 60 829 patients 
who were eligible for the PEGASUS trial but not on a 
P2Y12 inhibitor at 1-year post-MI was US$684 million. 
The estimated number of cardiovascular deaths, MI 
or strokes averted over a 3-year time horizon by initi-
ation of ticagrelor in this population was 773, which 
translates into a cost of US$885 000 per cardiovascular 
event averted. In the sensitivity analysis, when the esti-
mated clinical efficacy was varied by 25% above and 
below the point estimate reported in the PEGASUS 
trial, the cost per cardiovascular event averted ranged 
from US$709 000 to US$1.2 million. The estimated 
number of additional bleeding events over a 3-year 
time horizon following initiation of ticagrelor in this 
population was 754.
The Wholesale Acquisition Cost for a 1-year supply 
of 75 mg generic clopidogrel daily was US$84, with 
an estimated total cost of US$15.3 million to initiate 
and continue clopidogrel in the same population of 
60 829 patients for a 3-year time horizon. Estimating a 
similar number of cardiovascular deaths, MI or strokes 
averted as would be achieved with ticagrelor over a 
3-year time horizon, this translates into US$19 800 per 
cardiovascular event averted. In the sensitivity anal-
ysis, when the estimated clinical efficacy was varied by 
25% above and below the point estimate, the cost per 
cardiovascular event averted ranged from US$15 800 
to US$26 400.
DISCUSSION
We assessed the implications of the PEGASUS-TIMI 54 
trial in a real-world population of patients drawn from 
the ACTION Registry–GWTG, including the number 
of eligible patients, current use of P2Y12 inhibitors and 
the cost and ischaemic consequences of long-term 
P2Y12 inhibition. Among 273 328 patients with MI in the 
ACTION Registry–GWTG, 112 222 (41.1%) met eligi-
bility for the PEGASUS trial. Among patients eligible 
for PEGASUS, only 27.5% were on a P2Y12 inhibitor 
at 1 year post-MI. Initiating and continuing ticagrelor 
in patients eligible for PEGASUS who were not yet on 
a P2Y12 inhibitor at 1-year post-MI would cost an esti-
mated US$885 000 per MI, stroke or death averted over 
a 3-year time horizon. The cost per ischaemic event 
averted was much lower for generic clopidogrel. These 
findings suggest that P2Y12 inhibitors are not routinely 
used in long-term care of patients with a prior history of 
MI. Adoption of the PEGASUS strategy in clinical prac-
tice would result in a large increase in P2Y12 use, and 
the cost per cardiovascular event averted would vary 
dramatically with the choice of P2Y12 inhibitor.
Evidence supporting long-term P2Y12 use in patients with 
prior myocardial infarction
Although a number of studies have investigated the 
long-term use of DAPT after PCI, investigation of 
the clinical efficacy of DAPT in long-term manage-
ment of patients with a prior MI is more limited. The 
Figure 1 Identification of patients eligible for PEGASUS in the ACTION Registry–GWTG (Acute Coronary Treatment and 
Intervention Outcomes Network Registry–Get With The Guidelines) and analysis cohort. SHS, Symphony Health Solutions.
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CHARISMA trial failed to demonstrate a clinical benefit 
from long-term clopidogrel use when added to aspirin 
in a broad population of patients with elevated cardio-
vascular risk.3 However, a subgroup analysis of this trial 
suggested a potential benefit of P2Y12 inhibitor use 
among patients with a prior history of MI.4 These find-
ings were supported by the PEGASUS-TIMI 54 trial, in 
which the addition of ticagrelor to background aspirin 
therapy resulted in a 1.27% reduction in the rate of 
cardiovascular death, MI or stroke among patients with 
a remote history of MI and an additional risk factor.7 
In both studies, the addition of long-term P2Y12 inhi-
bition was not associated with a reduction in all-cause 
mortality. However, given the implications for ischaemic 
events, clinical practice guidelines state the continua-
tion of DAPT may be reasonable among patients with a 
prior MI between 1 and 3 years earlier who have toler-
ated DAPT without bleeding complications.6
Applicability of the PEGASUS trial to real-world practice
Despite the potential benefit of long-term P2Y12 inhib-
itors therapy in patients with prior MI, the number 
of patients who might benefit is unknown. The popu-
lation evaluated in clinical trials may not represent 
the population of patients in clinical practice. In the 
present study, less than half of all patients with MI met 
the PEGASUS eligibility criteria. These findings are 
consistent with prior studies that have demonstrated 
the differences between patients represented in clinical 
trials and patients seen in clinical practice.12
Indiscriminate use of P2Y12 inhibitors among 
patients with a prior MI may result in the treatment 
of a lower risk population than represented by the 
PEGASUS trial and, potentially, a smaller effect on 
ischaemic events. In the present study, one in five 
patients with prior MI was not PEGASUS eligible, 
because the patient lacked an additional high-risk 
feature for ischaemic events. Furthermore, nearly 
14% of patients were ineligible, because they were on 
an anticoagulant. The use of P2Y12 inhibitors in these 
patients may result in significantly higher bleeding 
risk, which outweighs the ischaemic benefit of P2Y12 
inhibitors. These findings highlight the importance 
of close scrutiny of eligibility as it applies to individual 
patients in routine practice.
Long-term use of P2Y12 inhibitors after myocardial infarction 
in clinical practice
P2Y12 inhibitors were infrequently used in the long-
term management of patients with MI in the ACTION 
Registry–GWTG. It will be important to study the poten-
tial changing use of this therapy over time to understand 
the clinical effectiveness and safety of P2Y12 inhibitors in 
real-world settings, both among patients who meet eligi-
bility criteria for the randomised trials of this therapy 
and among the more than 50% of patients with prior MI 
who are not represented in the randomised trials of this 
therapy. In addition, our study suggests that non-clin-
ical factors such as insurance status influences the use 
of P2Y12 in current practice. Identifying and addressing 
barriers to the use of P2Y12 inhibitors will be important 
to guide optimal use in eligible patients. Further, we 
found patients at higher bleeding risk were less likely 
to receive long-term P2Y12 inhibitors in current prac-
tice. This is consistent with the thoughtful use of P2Y12 
inhibitors, as a trade-off between decreasing ischaemic 
risk and increasing bleeding risk is intrinsic to the long-
term use of P2Y12 inhibitors. Ensuring P2Y12 inhibitors 
are used in patients with higher predicted ischaemic 
benefit and lower bleeding risk may further ensure 
Table 1 Comparison of patients eligible for the PEGASUS 
(60 mg ticagrelor with patients eligible for PEGASUS 
identified from the ACTION Registry-GWTG
Characteristics
PEGASUS trial 
patients
 (n=7045)
PEGASUS 
trial eligible in 
the ACTION 
Registry–GWTG
 (n=83 871)
Patient demographics
  Age, mean (SD) 65.2 (8.4) 69.4 (9.5)
  Men, n (%) 5384 (76.4) 51 117 (60.9)
  White 6077 (86.3) 73 232 (87.3)
Patient medical history
  Diabetes, n (%) 2308 (32.8) 29 704 (35.4)
  Hypertension, n (%) 5461 (77.5) 64 472 (76.9)
  Peripheral arterial 
disease, n (%)
368 (5.2) 6401 (7.6)
  Prior MI, n (%) 1168 (16.6) 15 763 (18.8)
  Chronic kidney disease, 
n (%)
   ≥Stage 3 1547/6955 (22.2) 25 551 (30.5)
MI characteristics and 
management
  Presentation, n (%)
   STEMI 3757/7035 (53.4) 33 609 (40.1)
   NSTEMI 2842/7035 (40.4) 50 262 (59.9)
Medications
  Beta-blocker 5796 (82.3) 77 552 (92.5)
  ACE inhibitor or ARB 5631 (79.9) 57 352 (68.4)
  Statin 6495 (92.2) 77 181 (92.0)
  Aspirin at any dose 7036 (99.9) 81 155 (96.8)
Ischaemic outcomes at 3 
years
  MI 285 (4.5%) 10 889 (13.0%)
  Stroke 91 (1.5%) 1447 (1.7%)
ACTION Registry–GWTG, Acute Coronary Treatment and 
Intervention Outcomes Network Registry–Get With The Guidelines; 
ARB, angiotensin II receptor blocker; MI, myocardial infarction; 
NSTEMI, non-ST-elevation myocardial infarction; STEMI, ST-
elevation myocardial infarction.
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Table 2 Characteristics of patients eligible for PEGASUS in the ACTION Registry–GWTG by P2Y12 use 1 year after MI
Characteristics
Overall cohort
 (n=83 871)
On DAPTat1 year post-MI
 (n=23 042)
NoDAPT 1 year post-MI
 (n=60 829) p Value
Patient demographics
  Age, mean (SD) 69.4 (9.5) 69.3 (9.0) 69.4 (9.6) 0.03
  Men, n (%) 51 117 (60.9) 14 165 (61.5) 36 952 (60.7) 0.06
  Race, n (%)
   White 73 232 (87.3) 20 562 (89.2) 52 670 (86.6) <0.001
   African-American 8067 (9.6) 1 858 (8.1) 6209 (10.2) <0.001
   Asian 1525 (1.8) 390 (1.7) 1135 (1.9) 0.09
   Other 1047 (1.3) 232 (1.0) 815 (1.3) <0.001
  Hispanic or Latino, n (%) 4415 (5.3) 1066 (4.6) 3349 (5.5) <0.001
  Insurance, n (%)
   None 6037 (7.2) 672 (2.9) 5365 (8.8) <0.001
   Private 21 176 (25.2) 7069 (30.7) 14 107 (23.2) <0.001
   Medicaid or Medicare 55 595 (66.3) 15 127 (65.6) 40 468 (66.5) 0.02
   Other 1063 (1.3) 174 (0.8) 889 (1.5) <0.001
Patient medical history
  Body mass index, mean (SD) 29.4 (9.4) 29.7 (10.4) 29.3 (9.0) <0.001
  Diabetes, n (%) 29 704 (35.4) 7497 (32.5) 22 207 (36.5) <0.001
   Insulin therapy, n (%) 6262 (7.5) 1370 (5.9) 4892 (8.0) <0.001
  Hypertension, n (%) 64 472 (76.9) 17 196 (74.6) 47 276 (77.7) <0.001
  Dyslipidaemia, n (%) 43 458 (51.8) 11 941 (51.8) 31 517 (51.8) 0.98
  Current/recent smoker, n (%) 23 253 (27.7) 5948 (25.8) 17 305 (28.4) <0.001
  Cerebrovascular disease, n (%) 3742 (4.5) 882 (3.8) 2860 (4.7) <0.001
  Peripheral arterial disease, n (%) 6401 (7.6) 1465 (6.4) 4936 (8.1) <0.001
  Prior PCI, n (%) 17 094 (20.4) 4336 (18.8) 12 758 (21.0) <0.001
  Prior CABG, n (%) 267 (0.3) 58 (0.3) 209 (0.3) 0.04
  Prior MI, n (%) 15 763 (18.8) 3807 (16.5) 11 956 (19.7) <0.001
  Prior heart failure, n (%) 5615 (6.7) 996 (4.3) 4619 (7.6) <0.001
  Chronic kidney disease, n (%)
   Stage 1 or 2 57 663 (68.8) 16 761 (72.7) 40 902 (67.2) <0.001
   ≥Stage 3 25 551 (30.5) 6075 (26.4) 19 476 (32.0) <0.001
  Anaemia, n (%) 19 062 (22.7) 4115 (17.9) 14 947 (24.6) <0.001
  Chronic lung disease, n (%) 9723 (11.6) 2143 (9.3) 7580 (12.5) <0.001
MI characteristics and management
  Presentation, n (%)
   STEMI 33 609 (40.1) 11 146 (48.4) 22 463 (36.9) <0.001
   NSTEMI 50 262 (59.9) 11 896 (51.6) 38 366 (63.1) <0.001
  PCI, n (%) 55 973 (66.7) 19 852 (86.2) 36 121 (59.4) <0.001
   DES 37 510 (44.7) 15 085 (65.5) 22 425 (36.9) <0.001
   BMS 14 460 (17.2) 3872 (16.8) 10 588 (17.4) 0.04
  CABG 10 463 (12.5) 949 (4.1) 9514 (15.6) <0.001
  Bleeding Risk Score, n (%)
   Very low 12 262 (14.8) 3529 (15.6) 8733 (14.6) <0.001
   Low 42 931 (51.9) 12 336 (54.4) 30 595 (51.0) <0.001
   Moderate 24 291 (29.4) 6226 (27.5) 18 065 (30.1) <0.001
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optimal patient outcomes with this therapy in clinical 
practice.7 18
Although the focus of our study relates to the implica-
tions of increasing the use of DAPT beyond 1 year post-MI, 
it is worth noting that 23% of patients in the ACTION-
GWTG Registry did not receive a P2Y12 inhibitor at the 
time of discharge. This gap in care delivery is consistent 
with prior studies19–21 and suggests an opportunity to 
improve patient outcomes through more consistent use 
of P2Y12 at discharge for MI.
Cost and clinical consequences of long-term P2Y12 inhibitor 
use
Although the PEGASUS trial specifically evaluated tica-
grelor, the CHARISMA substudy suggests a potential 
class effect of long-term P2Y12 inhibition among patients 
with prior MI.4 This finding has important implications 
for the costs of expanding P2Y12 use in clinical practice. 
Clopidogrel has been available as a generic medication 
since 2012 and is less expensive than ticagrelor. As a 
result, the estimated cost per ischaemic event averted 
differs by nearly 45-fold between the two alternatives. 
The cost relative to clinical impact of a given therapy 
is becoming increasingly relevant, as payers apply these 
considerations in coverage decisions and provider 
organisations with Accountable Care Organization 
contracts seek to optimise outcomes at lower cost.22 
Based on data from the Healthcare Utilization Project, 
the median cost of MI admissions in the USA in 2013 was 
US$15 402, and the median cost of stroke admissions 
Characteristics
Overall cohort
 (n=83 871)
On DAPTat1 year post-MI
 (n=23 042)
NoDAPT 1 year post-MI
 (n=60 829) p Value
  High 2931 (3.6) 546 (2.4) 2385 (4.0) <0.001
  Very high 239 (0.3) 43 (0.2) 196 (0.3) 0.001
Discharge medications
 P2Y12 inhibitor, n (%)
  None 19 111 (22.8) 1238 (5.4) 17 873 (29.4) <0.001
  Clopidogrel 51 075 (60.9) 17 297 (75.1) 33 778 (55.5) <0.001
  Ticlopidine 71 (0.1) 19 (0.1) 52 (0.1) 0.89
  Prasugrel 13 355 (15.9) 4394 (19.1) 8961 (14.7) <0.001
  Ticagrelor 375 (0.4) 139 (0.6) 236 (0.4) <0.001
 Beta-blocker 77 552 (92.5) 21 559 (93.6) 55 993 (92.0) <0.001
 ACE inhibitor or ARB 57 352 (68.4) 16 539 (71.8) 40 813 (67.1) <0.001
 Statin 77 181 (92.0) 21 782 (94.5) 55 399 (91.1) <0.001
 Aspirin at any dose 81 155 (96.8) 22 548 (97.9) 58 607 (96.3) <0.001
Medications at 1 year
 P2Y12 inhibitor
  None 60 829 (72.5) 0 (100.0) 60 829 (100.0)
  Clopidogrel 18 255 (21.8) 18 255 (79.2) 0
  Ticlopidine 9 (0.0) 9 (0.0) 0
  Prasugrel 4089 (4.9) 4089 (17.7) 0
  Ticagrelor 693 (0.8) 693 (3.0) 0
 Anticoagulation
  Warfarin 1832 (2.2) 397 (1.7) 1435 (2.4) <0.001
  Dabigatran 139 (0.2) 41 (0.2) 98 (0.2) 0.59
  Rivaroxaban 95 (0.1) 20 (0.1) 75 (0.1) 0.16
  Apixiban 4 (0.0) 0 (0.0) 4 (0.0) 0.22
 Beta-blocker 42 597 (50.8) 17 723 (76.9) 24 874 (40.9) <0.001
 ACE inhibitor or ARB 33 658 (40.1) 13 994 (60.7) 19 664 (32.3) <0.001
 Statin 41 273 (49.2) 17 797 (77.2) 23 476 (38.6) <0.001
ACTION Registry–GWTG, Acute Coronary Treatment and Intervention Outcomes Network Registry–Get With The Guidelines; ARB, 
angiotensin II receptor blocker; BMS, bare-metal stent; CABG, coronary artery bypass grating; DAPT, dual antiplatelet therapy; DES, drug-
eluting stent; MI, myocardial infarction; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, 
ST-elevation MI.
Table 2 Continued 
group.bmj.com on May 25, 2017 - Published by http://openheart.bmj.com/Downloaded from 
Open Heart
8 Bradley SM, et al. Open Heart 2017;4:e000580. doi:10.1136/openhrt-2016-000580
was US$8949.23 With this as a comparator, the cost of 
additional clopidogrel use would be nearly offset by the 
cost of averted events, whereas the cost of additional 
ticagrelor use would be more than the cost of averted 
events. However, once the cost of bleeding events are 
considered, both therapies may be more costly than 
discontinuation of P2Y12 inhibitors. Additional studies 
from clinical practice are needed to further inform the 
effectiveness of these two therapies on ischaemic events 
and the cost consequences of specific P2Y12 inhibitors 
used in long-term management.
Strengths and limitations
Strengths of this study include the national perspec-
tive and pharmacy claims data to evaluate long-term 
P2Y12 use in clinical practice. Limitations of our study 
include the lack of detailed clinical data in follow-up 
from the index MI, thus requiring extrapolation of clin-
ical data at the time of the MI to estimate eligibility for 
the PEGASUS trial. As a result, our study may underes-
timate the proportion of patients who would have been 
excluded from the PEGASUS trial. We were also unable 
to adjust for important differences in patient selection 
necessary to perform comparative effectiveness anal-
yses between use and non-use of P2Y12 inhibitors and 
different P2Y12 inhibitors. We lacked data on some 
comorbid conditions that were exclusion criteria for the 
PEGASUS trial. As a result, our study may overestimate 
the proportion of real-world patients who would have 
met eligibility criteria for the PEGASUS trial. We were 
unable to match 25% of patients eligible for PEGASUS 
to pharmacy claims data. Our study is limited by a time 
period that precedes the publication of the PEGASUS 
trial in 2014. However, the intent of our study was to 
describe how clinical practice might be influenced by 
this study, and future studies are needed to understand 
practice changes in P2Y12 inhibitor use subsequent to 
the publication of this trial. Although we compared the 
estimated ischaemic clinical consequences of increasing 
the use of long-term P2Y12 therapy, increased bleeding 
is a risk of long-term use of this therapy. However, 
differences in the reporting of bleeding events across 
the PEGASUS trial and the CHARISMA substudy limit 
the ability to extrapolate the estimated impact beyond 
what has been reported in these trials. We were limited 
in our evaluation to ischaemic events using point esti-
mates from the randomised controlled trials for the 
time horizons studied. Further study of P2Y12 therapies 
in routine clinical practice is needed to further under-
stand the ischaemic benefit and bleeding risk trade-offs 
of these therapies in real-world use. Finally, we did not 
attempt to convert clinical consequences to health util-
ities (ie, quality-adjusted life years), as our intent was to 
describe the costs and ischaemic clinical consequences 
of expanding P2Y12 inhibitor use rather than the cost-ef-
fectiveness of the therapy.
CONCLUSION
A minority of patients in the ACTION Registry–GWTG 
were on a P2Y12 inhibitor beyond 1 year post-MI. 
Applying PEGASUS trial findings to our patient cohort 
would result in a large increase in P2Y12 inhibitor use. 
The estimated cost per ischaemic event averted is 
nearly 45-fold larger with long-term ticagrelor than 
with generic clopidogrel. Continued study of long-
term P2Y12 inhibition on patient outcomes and cost 
of care is needed to further guide optimal use of this 
therapy.
Figure 2 Proportion of patients eligible for PEGASUS in the ACTION Registry–GWTG (Acute Coronary Treatment and 
Intervention Outcomes Network Registry–Get With The Guidelines) on P2Y12 inhibitors over time. MI, myocardial infarction.
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Table 3 Patients eligible for PEGASUS in the ACTION Registry–GWTG characteristics by the use of a P2Y12 inhibitor at 1, 2 
and 3 years post-MI
Characteristics
On P2Y12 at
1 year post-MI
 (n=23 042)
On P2Y12 at
2 years post-MI
 (n=9661)
On P2Y12 at
3 years post-MI
 (n=5246) p Value
Patient demographics
  Age, mean (SD) 69.3 (9.0) 69.3 (9.1) 69.1 (8.9) 0.53
  Men, n (%) 14 165 (61.5) 5890 (61.0) 3194 (60.9) 0.57
  Race, n (%)
   White 20 562 (89.2) 8527 (88.3) 4639 (88.4) 0.02
   African-American 1858 (8.1) 848 (8.8) 446 (8.5) 0.09
   Asian 390 (1.7) 189 (2.0) 107 (2.0) 0.10
   Other 232 (1.0) 97 (1.0) 54 (1.0) 0.99
Hispanic or Latino, n (%) 1066 (4.6) 494 (5.1) 274 (5.2) 0.05
  Insurance, n (%)
   None 672 (2.9) 284 (2.9) 166 (3.2) 0.63
   Private 7069 (30.7) 2 916 (30.2) 1 558 (29.7) 0.32
   Medicaid or Medicare 15 127 (65.6) 6 387 (66.1) 3 482 (66.4) 0.51
   Other 174 (0.8) 74 (0.8) 40 (0.8) 0.99
Patient medical history
  Body mass index 29.7 (10.4) 29.9 (11.3) 30.0 (11.2) 0.22
  Diabetes, n (%) 7497 (32.5) 3257 (33.7) 1759 (33.5) 0.08
  Insulin therapy, n (%) 1370 (5.9) 590 (6.1) 320 (6.1) 0.82
  Hypertension, n (%) 17 196 (74.6) 7455 (77.2) 4040 (77.0) <0.001
  Dyslipidaemia, n (%) 11 941 (51.8) 5117 (53.0) 2763 (52.7) 0.13
  Current/recent smoker, n (%) 5948 (25.8) 2588 (26.8) 1445 (27.5) 0.02
  Cerebrovascular disease, n (%) 882 (3.8) 399 (4.1) 214 (4.1) 0.38
  Peripheral arterial disease, n (%) 1465 (6.4) 652 (6.7) 347 (6.6) 0.39
  Prior PCI, n (%) 4336 (18.8) 1935 (20.0) 1045 (19.9) 0.02
  Prior CABG, n (%) 58 (0.3) 26 (0.3) 12 (0.2) 0.89
  Prior MI, n (%) 3807 (16.5) 1733 (17.9) 947 (18.1) 0.001
  Prior heart failure, n (%) 996 (4.3) 439 (4.5) 213 (4.1) 0.37
  Chronic kidney disease, n (%)
   Stage 1 or 2 16 761 (72.7) 6988 (72.3) 3855 (73.5) 0.32
   ≥Stage 3 6075 (26.4) 2578 (26.7) 1346 (25.7) 0.40
  Anaemia, n (%) 4115 (17.9) 1786 (18.5) 956 (18.2) 0.38
  Chronic lung disease, n (%) 2143 (9.3) 886 (9.2) 459 (8.7) 0.46
MI characteristics and management
  Presentation, n (%)
   STEMI 11 146 (48.4) 4661 (48.2) 2542 (48.5) 0.96
   NSTEMI 11 896 (51.6) 5000 (51.8) 2704 (51.5) 0.96
  PCI indication, n (%) 19 852 (86.2) 8102 (83.9) 4379 (83.5) <0.001
   DES 15 085 (65.5) 6112 (63.3) 3280 (62.5) <0.001
   BMS 3872 (16.8) 1564 (16.2) 844 (16.1) 0.25
   CABG 949 (4.1) 471 (4.9) 268 (5.1) <0.001
  Bleeding Risk Score, n (%)
   Very low 3529 (15.6) 1404 (14.8) 749 (14.5) 0.06
   Low 12 336 (54.4) 5170 (54.4) 2852 (55.1) 0.53
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On P2Y12 at
1 year post-MI
 (n=23 042)
On P2Y12 at
2 years post-MI
 (n=9661)
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3 years post-MI
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angiotensin II receptor blocker; BMS, bare-metal stent; CABG, coronary artery bypass grating; DES, drug-eluting stent; MI, myocardial 
infarction; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-elevation MI.
Table 3 Continued 
group.bmj.com on May 25, 2017 - Published by http://openheart.bmj.com/Downloaded from 
US clinical practice
Implications of the PEGASUS-TIMI 54 trial for
and Thomas M Maddox
Steven A Farmer, Jason H Wasfy, Javier Alfonso Valle, Amneet Sandhu 
Steven M Bradley, Gregory P Hess, Patrick Stewart, Ehrin J Armstrong,
doi: 10.1136/openhrt-2016-000580
2017 4: Open Heart 
 http://openheart.bmj.com/content/4/1/e000580
Updated information and services can be found at: 
These include:
References
 #BIBLhttp://openheart.bmj.com/content/4/1/e000580
This article cites 21 articles, 9 of which you can access for free at: 
Open Access
 http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on May 25, 2017 - Published by http://openheart.bmj.com/Downloaded from 
